Back to Top

Information For Authors

PHAGE: Therapy, Applications, and Research follows the standards, guidelines, and best practices set forth by the Committee on Publication Ethics (COPE; https://publicationethics.org/), the International Committee of Journal Medical Editors (ICJME; http://www.icmje.org/), and the American Medical Association (www.ama-assn.org).

Submitting Your Manuscript

PHAGE welcomes format-neutral manuscripts for first-time submissions. Newly submitted manuscripts will not be un-submitted for formatting issues.  However, after the initial peer review process, revised submissions must follow correct journal formatting and file guidelines, as described in the Instructions for Authors.

ORCID IDs

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

PEER REVIEW POLICIES:
PHAGE: Therapy, Applications, and Research is a single-blinded peer-reviewed journal. All submissions are subject to peer review. A minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Following peer review, the Editor and/or Associate Editors will determine if the paper should be accepted, require revision, or is unacceptable for publication.
Time in Review

The journal strives to maintain a short, but thorough peer-review process. The average time in review is 21 days but the Editor will strive to expedite manuscript handling if circumstances dictate.

Confidentiality in Peer Review
Editors and reviewers must maintain strict confidentiality of manuscripts during the peer-review process. Sharing a manuscript in whole or in part, outside the scope of what is necessary for assessment, is impermissible prior to an accepted manuscript's official publication date.

Sharing of Materials during Peer Review
Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review unless it violates the privacy or confidentiality of human research subjects.

Papers Authored by the Editor-in-Chief and/or Associate Editors
The Editor-in-Chief and Associate Editors will recuse themselves from participating in the review process of any manuscript in which there is a potential or actual competing interest.
 

MANUSCRIPT SUBMISSION

All manuscripts must be submitted through our online peer review sitea:
http://mc.manuscriptcentral.com/PHAGE
***Please read all instructions below before proceeding.***

 

ATTENTION:  To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

Create an Account in Manuscript Central
Submissions to PHAGE: Therapy, Applications, and Research are managed through our online peer review system, Manuscript Central.  If you do not already have an account in Manuscript Central specifically for Phage Therapy and Research, you will need to create one. Once you create your account, you may log in to the system to begin your submission. Each listed author on a submission must either already have an account, or have one created, in the system.  Before creating an account for your coauthor(s), search the database using your coauthors' email addresses to ascertain if an account already exists. If no account exists, you may create one on behalf of your coauthor(s). Please ensure the ACCURACY of created accounts.  For technical assistance, contact AuthorServices@liebertpub.com

MANUSCRIPT TYPES AND WORD LIMITS

Word limits do not include the title, abstract, authors and affiliations, keywords, figure legends, tables, acknowledgements, authorship confirmation statement, author disclosure statements, acknowledgments, or references.  Exceptions to the limitations set herein are permissible at the discretion of the Editor(s).

 

Review Articles

5,000 word limit, 150 references, and a total of 10 figures and tables

Original Articles

3,000 word limit, 100 references, and a total of 10 figures and tables

Perspectives

1,500 word limit, 5 references, and a total of 2 figures and/or tables

Commentaries

1,500 word limit, 3 references, and a total of 1 figure OR table

Editorials

1,000 word limit, 5 references, and a total of 1 figure OR table

Letters to the Editor

500 word limit, 4 references and 1 table OR figure

Bacteriophage Introductions**

2,500 word limit, and a total of 4 figures and/or tables

**The editor for this section is Dr. Andrew Millard, University of Leicester.  This category focuses on the genomic and basic phenotypic properties of newly isolated bacteriophages with the view to announcing newly isolated bacteriophages to the research community. Please direct inquiries regarding Bacteriophage Introductions to Dr. Millard at:  adm39@le.ac.uk


Keywords (Areas of Expertise to be used for peer review)
While uploading your manuscript files, you will be asked to select 4-6 keywords from the drop-down list of pre-selected terms for the peer review process. These keywords will assist in the selection of skilled reviewers in the field for the purposes of peer review.  They may be same, or different, from those you enter as search terms for your paper.
 

PRESENTATION OF MANUSCRIPT (Please follow these requirements and sequence:)

Title Page:

Create an Effective Title

  • Manuscript titles should be brief, contain key terms, and clearly identify the purpose of the work conducted
  • Endeavor to limit the title to no more than 12-15 words
  • Titles should be direct and to the point.  Remember that the journal has a global readership, so clear and concise non-vernacular language is most effective
  • Avoid the use of specific locations in the title
  • Do not use proprietary/trademarked names in the title
  • Do not use acronyms in the title unless they are universally recognized, accepted, and do not require definition.

A title page of your submission must be included as part of your main text document (not as a separate file) and must include the following items:

  • The complete title of the article;
  • All contributing authors' full names, complete affiliation information, telephone numbers, and e-mail addresses);
  • A brief running title of no more than 45 characters, including spaces;
  • Denotation of the corresponding author and his/her complete contact information including address and email address;
  • Three (3) to six (6) manuscript keywords.  These keywords are entered manually and should identify the specific search terms related to the submission.

Authorship Confirmation Statement
Authorship statements may also be uploaded as a separate file, under the designation "Authorship Statement.” This statement should include a paragraph detailing each listed authors' contributions to and responsibilities for the manuscript as well as a statement that all co-authors have reviewed and approved of the manuscript prior to submission. Lastly, include a confirmation statement that the manuscript has been submitted solely to this journal and is not published, in press, or submitted elsewhere (posting on a non-peer-reviewed preprint server does not constitute prior publication).

Author Disclosure Statements
On a separate page within the manuscript file, following the Authorship Confirmation Statement page, include any financial conflicts of interest, actual or potential, for each listed author on the submission. If no conflicts exist, the authors must state, "No competing financial interests exist." Manuscripts submitted without Author Disclosure Statements will be returned so that a statement may be added.
For guidance, please visit the website for the International Committee of Journal Medical Editors (ICMJE) at www.icmje.org

Abstract Requirements:

  • The abstract must be in Word and included in the main text file, after the title page
  • Abstract should be structured.  (Include Background, Materials & Methods, Results, and Conclusions sections identified)
  • The abstract should briefly summarize the background and rationale of the study, and clearly summarize the results and conclusions of the work
  • Abstract should be no more than 150 words
  • References are not permitted in the abstract
  • Do not use proprietary or trade names in the abstract

 FILE NAMING:

  • Name all files in English and use only alphanumeric characters. Do not include spaces or use symbols, dots, lines, underscores, or dashes.
  • Figure files names should be formatted with first author's last name and the file type. (Ex:  SmithText; SmithTables; SmithFig3)

 Main Manuscript (Text) File:

After the title page and abstract, prepare the remainder of the text following this sequence of sections:

  • Introduction
  • Materials and Methods
  • Results
  • Discussion
  • Conclusion
  • Acknowledgments
  • Author Confirmation Statement(s)
  • Author Disclosure Statement(s)
  • References
  • Appendices (if applicable)
  • Supplementary Information (if applicable);  NOTE:  Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)

Figures:

  • Do not embed figures in manuscript file
  • Prepare and upload each figure as an individual .TIFF or .EPS file
  • Do NOT submit figures in Word, PowerPoint, PDF, Bitmap, .JPEG, or Excel.  These files will delay the handling of your submission
  • Line illustrations must be submitted at 900 DPI.
  • Halftones and color should be submitted at a minimum of 300 dpi.
  • Color art must be saved as CMYK - not RGB. (N.B., If RGB files are submitted, the files will be converted to CYMK and some color variation will occur.)
  • Black and white art must be submitted as grayscale – not RGB.

Additional Information on Converting Figure Files:

Converting Word or Excel files: The best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:

  • All files should be scanned at 100% size
  • At least 300 dpi
  • Final color mode: CMYK
  • Save file as: .tif, .tiff, or .eps

For further information on converting Power Point slides to acceptable formats, go to: www.liebertpub.com/MEDIA/pdf/ppconvert.pdf

Color Publication Costs: See Journal Fees.
 

Tables:

  • Prepare and save all tables in one Word file (.doc or .docx).
  • Do not include tables in the main manuscript text file; they should be prepared in a separate file
  • Do not embed tables within the body of the text.
  • Include a table number and a title for each supplied table. 
  • Use Arabic numerals to number tables.
  • Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences.
  • Define all acronyms and symbols used within the body of the table in table footnotes.
  • All other types of table footnotes should be designated using superscript letters, not symbols.
  • Name all table files in English and use only alphanumeric characters.  Do not include spaces or use symbols, dots, lines, underscores, or dashes.
  • Upload table file under the "Table" file designation
    NOTE:  Figures and tables are placed in proximity to their citations within the text as space permits. 

Supplementary Information:

When appropriate, we encourage the judicious use of online-only supplementary information (SI). All information/data in the SI should be referred to in the article text, including reference to specific tables and figures in the SI. Upload supplementary tables, figures, and legends as separate files, either as "supplementary file" or "supplementary file for review only." The manuscript should be written so that the paper which appears in the printed journal contains all data which are key to the conclusions and important for the reader to have direct access to when reading the paper. Other supporting data and text are appropriate for the supplementary section.

 

NOTE:  Links to external sites containing further information with regard to the study is not permitted, except in the case of clinical trial registration sites.

 

Order of Files During Submission:

Upload manuscript files to our system in the following order:

  • Manuscript/Main text file
  • Tables
  • Figure Legends
  • Figures
  • Author Contribution Statement
  • Supplementary files

Note:  There is a total limit of 200 MB per submission.

 

REFERENCES

In-Text Citations.  Cite all references appearing in the reference list in numerical order, as superscripted numbers (no parentheses) and outside sentence punctuation.  Reference List Preparation:

  • Prepare a numbered (not alphabetical) reference list, in the order of citation within text and double spaced, at the end of the text of the manuscript (do not upload the reference list as a separate file).  See formatting examples below, or refer to the American Medical Association Manual of Style, 10/e.
  • If more than three authors are listed on an article, list the first three authors then use et al. (not italic) after the third author's name.
  • Abbreviations of journal titles in reference section should follow the style of MEDLINE (http://www.ncbi.nlm.nih.gov/nlmcatalog).
  • If a work is in press, state the journal title in which it is to be published, and include "in press" in parenthesis in place of a volume and page range.
  • When references to unpublished sources/correspondence are used, supply the researcher's name and date.
  • Use inclusive page ranges (i.e., 123-128, not 123-28).

For Users of EndNote®

PHAGE: Therapy, Applications, and Research is not currently included in EndNote, but will be in the near future. For those authors using EndNote, please download the similar output style template for Human Gene Therapy.
NOTE:  The publisher of PHAGE: Therapy, Applications, and Research does not provide technical support for EndNote. If you have questions, click on the Support tab on EndNote's website for assistance.
 

Reference Style Examples:

  • Journal Article: (for all journal articles containing more than three authors, list the first three, followed by et al.)

Metz L.  Battling superbugs: How phage therapy went from obscure to promising.  IEEE Pulse. 2019;10(1):3-9.

  • Journal Article: (e-pub ahead of print or online-only article):

Dabrowska K. Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med Res Rev. 2019 Mar 19. doi: 10.1002/med.21572. [Epub ahead of print].

  • Book:

Clokie MRJ, Kropinski A, Lavigne R. Bacteriophages: Methods and Protocols: Volume IV.  Valley Stream, NY: Humana Press; 2018.

  • Chapter in a Book:

Anany H, Brovko LY, Arutyunov D, et al. Immobilization of intact phage and phage-derived proteins for detection and biocontrol purposes.  In: Clokie MRJ, Kropinski A, and Lavigne R; eds.   Bacteriophages: Methods and Protocols: Volume IV . Valley Stream, NY:  Humana Press; 2018: 89-105.

  • Website: Please follow this structure for website references, including capitalization and punctuation:

List author names (if available) and/or page name/title. Website article (or organization) title. Provide complete website URL. Include last accessed date.

  • Conference Proceedings:  Please follow this structure for Conference Proceeding references, including capitalization and punctuation:

List all Authors' (or) Editors' names (last name first, followed by first and middle initials). Conference title. Date of conference. Location of conference. City of publisher: Publisher; Year of publication. Complete number of pages in proceedings book.

  • Preprint:  Preprints may be cited in same manner as a journal article; discretion is recommended as preprints are by definition not peer-reviewed.

MANUSCRIPT REVISIONS

Do NOT create a new submission for revisions of already-submitted manuscripts. Detailed instructions for submitting revised manuscripts are provided in the email that is sent to the corresponding author along with the reviewers' comments. Revised submissions routinely will undergo further review by the same reviewers who assessed the original submission, members of the editorial board, and/or the editor(s). Contact the Editorial Office immediately if the deadline for your revised submission has expired. Please note that an invitation to revise any submission does not guarantee acceptance.
 

JOURNAL and PUBLISHER POLICIES

 

DATA SHARING

Submitted manuscripts that report the results of clinical trials must contain a data sharing statement with the following information:

  • Whether deidentified participant data (including data dictionaries) will be shared;
  • What data in particular will be shared;
  • Related documentation (i.e., study protocols, statistical analyses, etc.) will be available;
  • When the data will be available and for what length of time will it be available;
  • What access criteria data will be shared.

For more detailed information on the requirements, please visit the International Committee of Medical Journal Editors website at:  http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/.  An additional resource for information is available in reference no. 1.
Cited Reference:

1.       Taichman DB, Sahni P, Pinborg A, et al. Data sharing statements for clinical trials: a requirement of the International Committee of Medical Journal Editors.  Ann Intern Med  67(1):63-65; doi: 10.7326/M17-1028.

Internal Review Board Approvals/Waivers (as described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013.** If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.
If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.

**  https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

EXCLUSIVITY

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of a conference abstract.  If work was presented at a conference, supply the name, date, and location of the meeting as a footnote on the title page of the submission.

PREPRINT SERVERS

PHAGE: Therapy, Applications, and Research recognizes the growing popularity of community non-peer-reviewed preprint repositories such as bioRxiv, arXiv, ChemRxiv, PeerJ Preprints, etc. Deposition of a preprint on a preprint server will not impact consideration of any manuscript submitted to PHAGE: Therapy, Applications, and Research. The existence of a publicly available preprint should be declared upon submission.

USE OF ENGLISH LANGUAGE

All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in PHAGE: Therapy, Applications, and Research. For authors whose native language is not English, we recommend using a service that will aid in the translation and rewriting of material into correct and proper English usage. The Publisher offers this service for a fee prior to official submission. For more information, please contact: Editing@liebertpub.com Please note that employing the use of the Publisher's service is not required, and using it, or any other language editing service, does not guarantee acceptance of any paper. All submissions are subject to peer review.

ATTENTION:  To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

POST-ACCEPTANCE / PRODUCTION

All accepted manuscripts will go through copyediting, typesetting, figure sizing and placement, author proofing, corrections, revisions (from corrected proofs), online-ahead-of-print release, and lastly, issue assignment. Depending on the length and complexity of any accepted submission, these steps typically take 3-6 weeks from acceptance.  Changes or alterations to a submission are not permitted after acceptance, but should be addressed in page proofs.

COPYRIGHT AGREEMENT FORM

Upon acceptance of any manuscript, all authors will receive an email with detailed instructions and a unique, author-specific link to access and complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors' email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications. FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM WILL RESULT IN A DELAY OF PUBLICATION. The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright. Copyright forms may also be completed by logging in to the system using an author's credentials. After logging on, click on Author Center and complete the forms located under "Manuscripts I Have Coauthored."

Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc., unless alternate arrangements are made prior to publication, including CC-BY licensing (see below). By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.

OPEN ACCESS / CC-BY LICENSING

PHAGE: Therapy, Applications, and Research is a subscription-based peer-reviewed journal with Open Access options. Creative Commons CC-BY and CC-BY-NC licensing is available for all articles published open access for a standard Article Processing Charge (APC) of $3,200.00 USD. Please contact our Open Access Manager to order open access for your article. For more information about open access publishing, please visit our Liebert Open Access website.

PAGE PROOFS

Page proofs will be sent to the corresponding author as designated in Manuscript Central when the manuscript was submitted. It is the corresponding author's responsibility to share the page proofs with co-authors, if desired, and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors/sources.

ATTENTION:  To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

AUTHOR RESPONSE TO GALLEY PROOF

  • The corresponding author is responsible for returning corrected galley proofs generally within 72 hours of receipt. If the corresponding author does not respond within that timeframe, the manuscript may be delayed in the publication schedule, or published as is, at the discretion of the Editor and Publisher. If the corresponding author expects to be unavailable during the time the manuscript is in production, the publisher should be provided with an alternate contact. 
  • Only corrections directly related to errors in typesetting and/or layout will be allowed. Any changes related to content or that alter the outcome of a study will require the approval of  the Editor, and may require further peer review.

PERMISSIONS

When reproducing copyrighted material such as figures, tables, or excerpted text, the author(s) of the submitted paper must obtain permission from the original publisher and submit it concurrently with the manuscript. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al." and list the appropriate reference. All permissions must be supplied at the time of submission.  Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.

REUSE OF MATERIAL POSTED ON SOCIAL MEDIA

As material posted on social media platforms is usually not peer-reviewed content, it is not permitted as an official citation and/or reference.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

AUTHORSHIP

Definition of Authorship

Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria1:

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Non-Author Contributors
Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged in the Acknowledgments section with a description of their contribution to the work.

ORCID IDs

All authors are encouraged to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

Authorship Limit

There is a limit of 35 authors permitted on a single submission, but in cases where there are 20 or more co-authors, PHAGE: Therapy, Applications, and Research recommends that a collective group or consortium name be provided and the individual authors listed in the Acknowledgements.

Corresponding Author

One author should be designated as the corresponding author who will be responsible for communication between the authors and the journal editorial office(s) and publisher.  This individual will be responsible for ensuring all authors submit copyright forms and coordinating and responding to page proofs, as well as any managing any other necessary contact during the peer review and/or production process.
NOTE: Due to configuration restraints, the submission system permits only one author to be identified as the corresponding author of record.  However, we recognize that some submissions call for more than one corresponding author to be noted.  In such cases, select one author to be the main point of contact and/or corresponding author for all communications regarding the peer review process of the paper, but on the title page of the manuscript, designate additional co-corresponding authors by including an asterisk after the authors' names in the byline, and include an accompanying footnote on the title page that reads, "*Co-corresponding authors."  Please ensure that the title page of the submission page carries the full affiliation details and email addresses of all authors who should be noted as a corresponding author. If the paper is accepted for publication, the full contact information for all desginated co-authors will be listed at the end of the article as per usual journal style. 

Working Groups/Team Authorship
Working Groups or Teams may be listed in the manuscript byline, but the entire listing of names and affiliations should be included in the acknowledgment section of the manuscript. Do not list the names in a footnote on the title page.

Variations of Authorship
It is permissible to list up to three authors as co-first authors, or as contributing equally to the work. Include an asterisk (*) next to the authors' names who are considered as first authors. Include a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors."

Changes in Authorship 
Changes in authorship after submission or acceptance of a paper are strongly discouraged, but the editorial leadership recognizes that in certain circumstances, it may be required. The journal's policy for such cases is as follows:

  • A request to alter authorship must be made in writing from the corresponding author to the Editor-in-Chief, with a detailed explanation for the request, and the names and affiliations of the authors requiring addition and/or deletion.
  • Authorship may be altered after submission or acceptance of a paper ONLY with the expressed written approval of all authors named on the manuscript, as well as the individual(s) being added and/or deleted. The Publisher can provide a form for this, if needed.
  • Upon receipt of the request and all written approvals of all involved parties, the Editor-in-Chief will consider the request, render a decision, and notify the corresponding author.
  • There is a one-year post-publication statute of limitation on requests for alterations in authorship.
  • Post-publication changes or alterations to conference abstracts are prohibited.

***Important Note about Author Listing***

It is incumbent upon the submitting author to ensure the accuracy and inclusion of all contributing authors' names and affiliations upon original submission of the paper. All authors' names must be entered into the Journal's submission site.

AUTHOR DISCLOSURE STATEMENTS

1. Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.

2. Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.

3. Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.

4. Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.

5. Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

SELF-CITATION AND SELF-PLAGIARISM

PHAGE: Therapy, Applications, and Research is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

  • Correction Statements/Errata to published articles that require the reproduction of color figure(s) and/or table(s) will incur additional costs to the author(s).

RESEARCH FUNDER COMPLIANCE (FundRef)

Upon submission of a manuscript, the submitting agent will have an opportunity to enter funding/grant information. If funding information is entered correctly, the publisher will deposit the funding acknowledgements from the article as part of the standard metadata to FundRef. The entered information should include funder names, funder IDs (if available), and associated grant numbers.  Special care should be taken when entering this information to ensure total accuracy. (See https://www.crossref.org/services/funder-registry/ for a listing of more than 13,000 international funding agencies.)

GOVERNMENT FUNDED RESEARCH

PHAGE: Therapy, Applications, and Research is fully NIH-, HHMI-, RUCK, and Wellcome Trust-compliant.

OPEN ACCESS

Our open access publishing solutions allow you to comply with the open access policies of your institution, government, and funding body. If you are employed or funded by the National Institute of Health (NIH), the Wellcome Trust, Research Councils UK (RCUK), or Howard Hughes Medical Institute (HHMI), you can find more information below:

  • NIH and HHMI Public Access Policy– In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final paginated version of the published article to PubMed Central (PMC) on behalf of the authors after a 12-month embargo period. Authors need not take any action. This service is provided free of charge. Authors who wish to remove the 12-month embargo period are encouraged to consider publishing with Open Option.
  • Wellcome Trust Policy– To easily comply, you can choose to have your article published open access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the Wellcome Trust.
  • Research Councils UK (RUCK) To easily comply, you can choose to have your article published Open Access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the RUCK.

POST-PUBLICATION CORRECTIONS

In the event an error is discovered after publication of an article, the corresponding author should submit the correction in writing to the editorial office for consideration. Changes in author affiliations or contact details due to relocation are not permitted after publication.

Corrections to meeting abstracts will be made only to the online version.  The Journal does not issue formal correction statements for corrections to meeting abstracts, regardless of the nature of the correction.

STUDY DESIGN AND ETHICS

Human Subjects

Patient Consent/Release

If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images and/or information of patients. The Journal does not provide a generic patient release form.

Any identifying information should not be published in descriptions or photographs unless the information is essential for scientific purposes and the patient (or parent/guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be submitted. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication.  Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, the manuscript should contain assurances/statements that such changes do not distort scientific meaning.

In keeping with patients' rights of privacy, the Journal does not require the submission of patient consent forms, but instead requires the author(s) to retain and archive all patient consent documentation. Upon submission of a manuscript for review, the authors must make a statement in a cover letter to the Editor/Journal which attests they have received and archived written patient consent.  A statement of patient consent must be included in the Methods section of the manuscript.

ETHICS OF EXPERIMENTATION

All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (http://ethics.od.nih.gov/.)

Ethical Treatment of Animals

All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles, and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.

RESPONDING TO ALLEGATIONS OF POSSIBLE MISCONDUCT

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.

DEFINITIONS OF SCIENTIFIC MISCONDUCT

Mary Ann Liebert, Inc., publishers follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  • Authorship Disputes: Deliberate misrepresentation of a scientist's contribution to the published work, or purposefully omitting the contributions of a scientist.
  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
  • Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
  • Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  • Plagiarism: Purposely claiming another's work or idea as your own constitutes misconduct and/or fraud.
  • Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.

RETRACTIONS

The journal and its publisher is committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction will be published.

ARCHIVING AND PRESERVATION

Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Your article will be easily searchable on Google, Google Scholar, and other search engines.

JOURNAL FEES

  • There are currently no submission fees to the Journal.
  • There no page charges for the Journal.
  • PHAGE: Therapy, Applications, and Research is currently waiving fees for color printing.
  • Open Access and Creative Commons licensing options are available. Contact our Open Access Manager for more information.
  • For pricing and purchasing reprints, contact our Reprints Manager.
  • Any collected fees for retracted and/or withdrawn articles are nonrefundable in any circumstance.

PUBLISHER

PHAGE: Therapy, Applications, and Research is owned by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801;  Tel:  914-740-2100; Email:  Info@liebertpub.com;  Website:  www.liebertpub.com/PHAGE

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.